AKOUOS
Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.
AKOUOS
Industry:
Biotechnology Health Diagnostics Pharmaceutical
Founded:
2016-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.akouos.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
162.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Global Site Tag IPv6 Google Analytics 4
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Fidelity
Fidelity investment in Series B - Akouos
PAG
PAG investment in Series B - Akouos
New Enterprise Associates
New Enterprise Associates investment in Series B - Akouos
Polaris Founders Capital
Polaris Founders Capital investment in Series B - Akouos
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Akouos
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Akouos
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series B - Akouos
RA Capital Management
RA Capital Management investment in Series B - Akouos
Surveyor Capital
Surveyor Capital investment in Series B - Akouos
Wu Capital
Wu Capital investment in Series B - Akouos
Key Employee Changes
Date | New article |
---|---|
2022-03-10 | Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer |
Official Site Inspections
http://www.akouos.com Semrush global rank: 2.96 M Semrush visits lastest month: 5.3 K
- Host name: 104.18.33.196
- IP address: 104.18.33.196
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago

More informations about "Akouos"
Akouos โ Our Mission: Healthy Hearing Available to All
Our Mission: Healthy Hearing Available to All. We are a precision genetic medicine company focused on developing gene therapies with the potential to restore, improve and preserve high โฆSee details»
Akouos - Crunchbase Company Profile & Funding
Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and โฆSee details»
Akouos - LinkedIn
Akouos wishes you a joyous holiday season filled with laughter, light, and happy times with loved ones. โฆmoreSee details»
Lilly Completes Acquisition of Akouos Expanding Efforts to Help โฆ
INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The โฆSee details»
Our Focus โ Akouos
The Akouos founding team has over 100 years of combined research experience characterizing inner ear structure-function relationships. The work of co-founder Dr. Richard J. Smith, โฆSee details»
Akouos - Funding, Financials, Valuation & Investors - Crunchbase
Akouos is registered under the ticker NASDAQ:AKUS . Their stock opened with $17.00 in its Jun 25, 2020 IPO. Akouos is funded by 15 investors. Fidelity and PAG are the most recent โฆSee details»
Akouos - Org Chart, Teams, Culture & Jobs - The Org
Akouos is a precision genetic medicine company focused on developing gene therapies with the potential to restore, improve and preserve high-acuity physiologic hearing. Industries. โฆSee details»
Akouos Company Profile - Office Locations, Competitors ... - Craft
Akouos is a precision genetic medicine company focused on developing gene therapies to treat hearing disorders. It advances candidate therapies that target sensory cells, such as inner hair โฆSee details»
Akouos - VentureRadar
" Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals โฆSee details»
Akouos - Contacts, Employees, Board Members, Advisors
Organization. Akouos . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 8. Number of Board โฆSee details»
Akouos - Overview, News & Similar companies | ZoomInfo.com
Who is Akouos. Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acu ity physiologic hearing โฆSee details»
Emmanuel Simons - CEO, President & Co-Founder at Akouos
Emmanuel J. (Manny) Simons, Ph.D., M.B.A., is CEO, President, and Co-Founder of Akouos. Dr. Simons is a scientist and entrepreneur with over fifteen years of experience in hearing science โฆSee details»
Lilly to Acquire Akouos to Discover and Develop Treatments for โฆ
Oct 18, 2022 Akouos has integrated expertise across otology, inner ear drug delivery, and gene therapy with the goal of addressing the needs of people living with disabling hearing loss โฆSee details»
Akouos Announces Expansion of Executive Team and Board of โฆ
Aug 5, 2020 incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of โฆSee details»
Akouos - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 28, 2025 Akouos is an acquired company based in Boston (United States), founded in 2016 by Manny Simons. It operates as a Developer of gene therapies to restore and preserve โฆSee details»
Startup Akouos Raises Millions for Sensorineural Hearing Loss โฆ
Aug 17, 2018 Akouos is focused on developing treatment for monogenic forms of sensorineural hearing loss (SNHL). SNHL, which accounts for 90 percent of hearing loss cases, is caused by โฆSee details»
Akouos - Updates, News, Events, Signals & Triggers - Crunchbase
Akouos may be growing as it was acquired by Eli Lilly for $500 million, indicating a significant valuation and investment in the company's potential. The acquisition by a major โฆSee details»
Akouos - workinbiotech.com
Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to โฆSee details»
Akouos investor presentations, pitch decks, slides and documents ...
Akouos Presentations & Investor Relations material Our Mission: Healthy Hearing Available to All We are a precision genetic medicine company focused on developing gene therapies with the โฆSee details»
Akouos Reports First Quarter 2022 Financial Results and Provides ...
May 12, 2022 incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of โฆSee details»